pharma · Dyslipidemia at High to Very High Cardiovascular Risk · Suspected or confirmed Gram negative infections
Menarini Asia-Pacific
A.Menarini Australia Pty Limited
A.Menarini Australia Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dyslipidemia at High to Very High Cardiovascular Risk, Suspected or confirmed Gram negative infection
Singapore, SG HQ
720 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Singapore, SG
- Employees
- 720
- Programs
- 2
- Drugs
- 15
- Patents
- 0
AMIL/25/Obi-Dys/001
Phase 3 · small molecule · Dyslipidemia at High to Very High Cardiovascular Risk
AMIL/25/Obi-Dys/001 for Dyslipidemia at High to Very High Cardiovascular Risk is a Phase 3 program (small_molecule) at A.Menarini Australia Pty Limited with 1 ClinicalTrials.gov record(s).
Internal code AMIL/25/Obi-Dys/001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- A.Menarini Australia Pty Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Dyslipidemia at High to Very High Cardiovascular Risk
- Status
- active
- Trials
- 1